The high BCL2 group showed better disease-free survival (p = 0.004) in HRc-positive breast cancers but there was no prognostic significance of BCL2 expression in HRc-negative breast cancers (Fig. S7). This evidence concerns the gene BCL2 and breast carcinoma.